Cargando…
Bioequivalence Study of Vortioxetine Hydrobromide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions
OBJECTIVE: This study compared the pharmacokinetic and safety profiles of generic and original vortioxetine hydrobromide tablets under fasting and fed conditions, and evaluated the bioequivalence of two vortioxetine formulations to obtain sufficient evidence for abbreviated new drug application. MET...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547006/ https://www.ncbi.nlm.nih.gov/pubmed/37795495 http://dx.doi.org/10.2147/DDDT.S428771 |
_version_ | 1785114973856333824 |
---|---|
author | Bai, Wanjun Song, Haojing Hu, Yiting Zhang, Xueyuan Wang, Xiaoru Guo, Caihui Qiu, Bo Dong, Zhanjun |
author_facet | Bai, Wanjun Song, Haojing Hu, Yiting Zhang, Xueyuan Wang, Xiaoru Guo, Caihui Qiu, Bo Dong, Zhanjun |
author_sort | Bai, Wanjun |
collection | PubMed |
description | OBJECTIVE: This study compared the pharmacokinetic and safety profiles of generic and original vortioxetine hydrobromide tablets under fasting and fed conditions, and evaluated the bioequivalence of two vortioxetine formulations to obtain sufficient evidence for abbreviated new drug application. METHODS: A randomized, open-label, two-formulation, single-dose, two-period crossover bioequivalence study was conducted under fasting and fed conditions (n = 32 per study). Eligible healthy Chinese subjects received a single 10-mg dose of the test or reference vortioxetine hydrobromide tablet, followed by a 28-day washout interval between periods. Serial blood samples were collected up to 72 h after administration in each period, and the plasma concentrations of vortioxetine were detected using a validated method. The primary pharmacokinetic (PK) parameters were calculated using the non-compartmental method. The geometric mean ratios for the PK parameters of the test drug to the reference drug and the corresponding 90% confidence intervals were acquired for bioequivalence analysis. A safety evaluation was performed throughout the study. RESULTS: Under fasting and fed conditions, the PK parameters of the test drug were similar to those of the reference drug. The 90% confidence intervals (CIs) of the geometric mean ratios of the test to reference formulations were 96.44–105.81% for peak concentration (C(max)), 97.94–105.05% for the area under the curve truncated at 72 hours (AUC(0-72 h)) under fasting conditions, 93.92–104.15% for C(max), and 96.67–102.55% for AUC(0-72 h) under fed conditions, all of which were within the accepted bioequivalence range of 80.00–125.00%. Both the test and reference formulations were well-tolerated, and no serious adverse events related to the study drug were reported during the study. CONCLUSION: The PK bioequivalence of the test and reference vortioxetine hydrobromide tablets in healthy Chinese subjects was established under fasting and fed conditions, which met the predetermined regulatory criteria. Both formulations were safe and well tolerated. |
format | Online Article Text |
id | pubmed-10547006 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-105470062023-10-04 Bioequivalence Study of Vortioxetine Hydrobromide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions Bai, Wanjun Song, Haojing Hu, Yiting Zhang, Xueyuan Wang, Xiaoru Guo, Caihui Qiu, Bo Dong, Zhanjun Drug Des Devel Ther Clinical Trial Report OBJECTIVE: This study compared the pharmacokinetic and safety profiles of generic and original vortioxetine hydrobromide tablets under fasting and fed conditions, and evaluated the bioequivalence of two vortioxetine formulations to obtain sufficient evidence for abbreviated new drug application. METHODS: A randomized, open-label, two-formulation, single-dose, two-period crossover bioequivalence study was conducted under fasting and fed conditions (n = 32 per study). Eligible healthy Chinese subjects received a single 10-mg dose of the test or reference vortioxetine hydrobromide tablet, followed by a 28-day washout interval between periods. Serial blood samples were collected up to 72 h after administration in each period, and the plasma concentrations of vortioxetine were detected using a validated method. The primary pharmacokinetic (PK) parameters were calculated using the non-compartmental method. The geometric mean ratios for the PK parameters of the test drug to the reference drug and the corresponding 90% confidence intervals were acquired for bioequivalence analysis. A safety evaluation was performed throughout the study. RESULTS: Under fasting and fed conditions, the PK parameters of the test drug were similar to those of the reference drug. The 90% confidence intervals (CIs) of the geometric mean ratios of the test to reference formulations were 96.44–105.81% for peak concentration (C(max)), 97.94–105.05% for the area under the curve truncated at 72 hours (AUC(0-72 h)) under fasting conditions, 93.92–104.15% for C(max), and 96.67–102.55% for AUC(0-72 h) under fed conditions, all of which were within the accepted bioequivalence range of 80.00–125.00%. Both the test and reference formulations were well-tolerated, and no serious adverse events related to the study drug were reported during the study. CONCLUSION: The PK bioequivalence of the test and reference vortioxetine hydrobromide tablets in healthy Chinese subjects was established under fasting and fed conditions, which met the predetermined regulatory criteria. Both formulations were safe and well tolerated. Dove 2023-09-29 /pmc/articles/PMC10547006/ /pubmed/37795495 http://dx.doi.org/10.2147/DDDT.S428771 Text en © 2023 Bai et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Clinical Trial Report Bai, Wanjun Song, Haojing Hu, Yiting Zhang, Xueyuan Wang, Xiaoru Guo, Caihui Qiu, Bo Dong, Zhanjun Bioequivalence Study of Vortioxetine Hydrobromide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions |
title | Bioequivalence Study of Vortioxetine Hydrobromide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions |
title_full | Bioequivalence Study of Vortioxetine Hydrobromide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions |
title_fullStr | Bioequivalence Study of Vortioxetine Hydrobromide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions |
title_full_unstemmed | Bioequivalence Study of Vortioxetine Hydrobromide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions |
title_short | Bioequivalence Study of Vortioxetine Hydrobromide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions |
title_sort | bioequivalence study of vortioxetine hydrobromide tablets in healthy chinese subjects under fasting and fed conditions |
topic | Clinical Trial Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547006/ https://www.ncbi.nlm.nih.gov/pubmed/37795495 http://dx.doi.org/10.2147/DDDT.S428771 |
work_keys_str_mv | AT baiwanjun bioequivalencestudyofvortioxetinehydrobromidetabletsinhealthychinesesubjectsunderfastingandfedconditions AT songhaojing bioequivalencestudyofvortioxetinehydrobromidetabletsinhealthychinesesubjectsunderfastingandfedconditions AT huyiting bioequivalencestudyofvortioxetinehydrobromidetabletsinhealthychinesesubjectsunderfastingandfedconditions AT zhangxueyuan bioequivalencestudyofvortioxetinehydrobromidetabletsinhealthychinesesubjectsunderfastingandfedconditions AT wangxiaoru bioequivalencestudyofvortioxetinehydrobromidetabletsinhealthychinesesubjectsunderfastingandfedconditions AT guocaihui bioequivalencestudyofvortioxetinehydrobromidetabletsinhealthychinesesubjectsunderfastingandfedconditions AT qiubo bioequivalencestudyofvortioxetinehydrobromidetabletsinhealthychinesesubjectsunderfastingandfedconditions AT dongzhanjun bioequivalencestudyofvortioxetinehydrobromidetabletsinhealthychinesesubjectsunderfastingandfedconditions |